E
71.12
-0.23 (-0.32%)
| Previous Close | 71.35 |
| Open | 71.46 |
| Volume | 1,822,847 |
| Avg. Volume (3M) | 4,499,813 |
| Market Cap | 41,811,451,904 |
| Price / Earnings (TTM) | 30.39 |
| Price / Earnings (Forward) | 31.25 |
| Price / Sales | 8.64 |
| Price / Book | 4.47 |
| 52 Weeks Range | |
| Earnings Date | 23 Apr 2025 - 28 Apr 2025 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.38 |
| Quarterly Revenue Growth (YOY) | 4.90% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.96% |
| Current Ratio (MRQ) | 4.18 |
| Operating Cash Flow (TTM) | 542.30 M |
| Levered Free Cash Flow (TTM) | 1.35 B |
| Return on Assets (TTM) | 8.26% |
| Return on Equity (TTM) | 16.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | Edwards Lifesciences Corporatio | Bullish | Bearish |
AIStockmoo Score
1.8
| Analyst Consensus | 3.0 |
| Insider Activity | 3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.80 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.90% |
| % Held by Institutions | 88.42% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Citigroup, 33.58%) | Buy |
| Median | 75.00 (5.46%) | |
| Low | 75.00 (Canaccord Genuity, 5.46%) | Hold |
| 75.00 (Baird, 5.46%) | Hold | |
| 75.00 (Truist Securities, 5.46%) | Hold | |
| Average | 80.60 (13.33%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 74.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 22 May 2025 | 95.00 (33.58%) | Buy | 74.79 |
| Piper Sandler | 13 May 2025 | 83.00 (16.70%) | Buy | 75.50 |
| 24 Apr 2025 | 80.00 (12.49%) | Buy | 75.13 | |
| Canaccord Genuity | 25 Apr 2025 | 75.00 (5.46%) | Hold | 76.04 |
| Baird | 24 Apr 2025 | 75.00 (5.46%) | Hold | 75.13 |
| Truist Securities | 11 Apr 2025 | 75.00 (5.46%) | Hold | 69.40 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOBO DONALD E JR | - | 73.68 | -816 | -60,123 |
| CHOPRA DAVEEN | - | 73.68 | -580 | -42,734 |
| LIPPIS DANIEL J. | - | 73.68 | -271 | -19,967 |
| ULLEM SCOTT B. | - | 73.68 | -1,200 | -88,416 |
| WOOD LARRY L | - | 73.68 | -988 | -72,796 |
| ZOVIGHIAN BERNARD J | 76.75 | 75.73 | -2,860 | -210,725 |
| Aggregate Net Quantity | -6,715 | |||
| Aggregate Net Value ($) | -494,761 | |||
| Aggregate Avg. Buy ($) | 76.75 | |||
| Aggregate Avg. Sell ($) | 74.45 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ZOVIGHIAN BERNARD J | Officer | 16 May 2025 | Disposed (-) | 5,816 | 78.00 | 453,648 |
| ZOVIGHIAN BERNARD J | Officer | 16 May 2025 | Acquired (+) | 5,816 | 78.00 | 453,648 |
| ZOVIGHIAN BERNARD J | Officer | 13 May 2025 | Disposed (-) | 2,771 | 75.50 | 209,211 |
| ZOVIGHIAN BERNARD J | Officer | 13 May 2025 | Acquired (+) | 2,771 | 75.50 | 209,211 |
| WOOD LARRY L | Officer | 11 May 2025 | Disposed (-) | 988 | 73.68 | 72,796 |
| BOBO DONALD E JR | Officer | 11 May 2025 | Disposed (-) | 816 | 73.68 | 60,123 |
| LIPPIS DANIEL J. | Officer | 11 May 2025 | Disposed (-) | 271 | 73.68 | 19,967 |
| CHOPRA DAVEEN | Officer | 11 May 2025 | Disposed (-) | 580 | 73.68 | 42,734 |
| ULLEM SCOTT B. | Officer | 11 May 2025 | Disposed (-) | 1,200 | 73.68 | 88,416 |
| ZOVIGHIAN BERNARD J | Officer | 11 May 2025 | Disposed (-) | 2,860 | 73.68 | 210,725 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |